The prevalence of chronic kidney disease (CKD) 7 has increased in recent decades, with Medicare costs increasing annually and exceeding $40 billion in 2009 in the US (1 ) . Strategies (2 ) and clinical practice guidelines (3 ) for early detection and management of CKD are aimed at slowing the progression of kidney disease and thus delaying or preventing the need for renal dialysis or kidney transplantation.
Serum creatinine and urinary albumin excretion are the primary biomarkers used for early detection and monitoring of CKD. Urine albumin measurement is the key marker for early kidney damage in diabetic nephropathy, with clinical practice guidelines recommending annual measurements in most people with diabetes (4, 5 ) . In 2013, the new international guideline on kidney disease (3 ) changed the classification of CKD to include, in addition to creatinine, the urine albumin excretion rate.
In contrast to the considerable recent progress toward standardization of measurement procedures for serum creatinine (6 ) , the state of agreement of routine clinical laboratory methods for measurement of urine albumin is unknown (7, 8 ) . Harmonized and specific measurement procedures are essential to allow the clinical use of the fixed decision points for urinary al-bumin excretion recommended by clinical practice guidelines for managing CKD (2) (3) (4) (5) .
The recent report from the National Kidney Disease Education Program (NKDEP) Laboratory Working Group and the IFCC Work Group for Standardization of Albumin in Urine identified information needed to develop recommendations for standardization (7 ) . Two key recommendations were to obtain and evaluate objective data on the current state of harmonization among routine measurement procedures for urine albumin and to clarify the range of urine matrix compositions for which routine measurement procedures are expected to provide good performance. In this report, we describe the findings and conclusions from an assessment of 17 routine measurement procedures by use of a large number of freshly collected urine samples.
Materials and Methods

PATIENT SAMPLES
Fresh aliquots of random patient urine samples (n ϭ 332) were obtained from residual samples submitted for routine medical care over a period of 10 weeks at Virginia Commonwealth University, University of Virginia, and Hamilton Health Sciences. The study was conducted according to institutional review boardapproved protocols for each institution. The samples were stored at 2-8°C immediately upon receipt. During each week, samples were equilibrated to ambient temperature (15-25°C), mixed thoroughly by inversion, and aliquoted into cryovials. The samples were stored at ambient temperature for Յ4 h. They were then placed into insulated containers maintained at 2-8°C (STP 319, Saf-T-Pak) for overnight delivery to testing locations. The samples were stored at 2-8°C upon receipt by the manufacturers' laboratories until testing. The maximum interval from collection to measurement was 5 days.
MEASUREMENT OF URINE ALBUMIN BY COMMERCIAL
MEASUREMENT PROCEDURES
Measurements were made for 16 quantitative procedures and 1 semiquantitative measurement procedure in the manufacturers' laboratories according to the instructions for use for each procedure (see Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol60/ issue3). Samples were equilibrated to ambient temperature (15-25°C) for 45 min and mixed thoroughly by inversion before analysis. Maximum allowable time from temperature equilibration to analysis was 4 h. To prevent evaporation, samples were not allowed to be uncapped for Ͼ20 min. Measurements were performed from the limit of quantification to 2000 mg/L. Samples with concentrations higher than the analytical measurement range (AMR) were diluted into the methods' AMR by use of the manufacturerrecommended diluent or normal saline if no diluent was recommended. Each sample was measured in quadruplicate with the samples in random order. Samples were measured during 10 separate weekly runs.
MEASUREMENT OF URINE ALBUMIN BY IDMS
An aliquot of each sample was frozen at Ϫ70°C and shipped to the Mayo Clinic Renal Function Laboratory on dry ice for measurement by a previously described liquid-chromatography-isotope dilution mass spectrometry (IDMS) measurement procedure (9, 10 ) were used for quantification. Calibrators were prepared by use of purified human serum albumin (A8763, Sigma Aldrich) in charcoal-stripped urine matrix (BioChemed Services), with the concentration determined by ultraviolet absorption spectroscopy (molar absorptivity at 280 nm of 38 533 L mol -1 cm -1 ). Two extracts of each urine sample were analyzed within a single run to obtain duplicate measurements. Quality control materials were analyzed in duplicate at the beginning and end of each run. Each measurement represented the mean of 2 transitions for each of the 3 peptides. Samples were measured in 5 independent runs.
MEASUREMENT OF STUDY QC MATERIALS
Study QC materials were prepared by adding purified monomeric human serum albumin (Ͼ99% purity, Sigma Aldrich) to a freshly collected 24-h urine sample from a healthy volunteer. Aliquots of QC materials were frozen at Ϫ70°C, shipped on dry ice to each testing location, and stored at Ϫ20°C until testing. Two or 3 concentrations of QC materials were analyzed per measurement procedure, depending on the AMR, in consecutive duplicates at the beginning and end of each run. Runs that included missing replicates or in which the manufacturer did not follow the experimental design protocol were excluded. Further details are provided in the online Supplemental Data.
FREEZE/THAW EFFECTS
The influence of freezing and thawing on measurement of urine albumin by the IDMS procedure was investigated by comparing results for aliquots of 29 nonfrozen urines stored at 4°C to aliquots of the same samples stored frozen for 42 h at Ϫ70°C and measured in the same runs. The influence of a freeze-thaw cycle on results for the routine measurement procedures was investigated by including 71 paired nonfrozen/frozen patient samples in the original study group. An aliquot was frozen at Ϫ70°C for 45 min, included in the same shipment as the companion nonfrozen aliquot, and allowed to thaw during shipment. The nonfrozen/frozen paired samples were blinded as to their identity and analyzed in random order in each run. Further details are provided in the online Supplemental Data.
STATISTICAL ANALYSIS
A comprehensive description of the statistical analyses is provided in the online Supplemental Data. In summary, imprecision components and bias were estimated by use of the error model shown in online Supplemental Table 2 . The model included contributions from within-run imprecision and position effects estimated from replicate measurements of patient samples, between-run imprecision estimated from QC samples, sample-specific effects estimated as the residual variance not explained by the other components, and bias on the basis of comparison of patient sample results to the IDMS results. All components in the error model were determined from ln(concentration) to improve symmetry of positive and negative differences and to ensure more homoscedastic variations. The influence of a single freeze-thaw cycle was determined by use of the same error model with the results after freezing and thawing as the dependent variable and the nonfrozen results as the independent variable. Outliers for the freeze-thaw assessment were identified by inspection of the difference plots and are shown in online Supplemental Table 3 . Runs excluded from imprecision estimates are shown in online Supplemental Table  4 . Outliers for bias assessments are shown in online Supplemental Table 5 .
Results
The study population (n ϭ 332) included patients diagnosed with CKD or with diseases known to have increased risk for CKD including diabetes mellitus, cardiovascular disease, and hypertension ( Table 1 ). The median age was 56 years (range 19 -88 years), and median estimated glomerular filtration rate calculated by use of the Chronic Kidney Disease Epidemiology Collaboration equation (11 ) 
). (14 ) .
The effects of a single freeze-thaw cycle for each measurement procedure are shown in online Supplemental Table 6 . For the IDMS procedure, the mean difference was 3.8%, with symmetric distribution and no trends over the concentration interval (see online Supplemental Fig. 1 ). Three routine measurement procedures exhibited statistically significant differences (P Ͻ 0.05), but mean differences between frozen and nonfrozen results were Ͻ1.0% for all routine procedures.
The percent differences for patient samples measured by use of routine measurement procedures vs IDMS are shown in Fig. 1 . Results were available for all 16 routine quantitative procedures for 232 of 332 samples and unavailable for 100 samples due to a variety of reasons such as inclement weather disrupting shipment, error flags, or laboratory accidents. The range of concentrations was limited to between 12 and 1064 mg/L urine albumin, which represented the largest lower limit of quantification (Cobas c 501) and the highest concentration measured by the Vitros 5600. Median differences between the largest positive and negative biases were 45%, 37%, and 42% in the concentrations intervals of 12-30, 31-200, and 201-1064 mg/L, respectively.
Difference plots for comparison of each routine measurement procedure with the IDMS procedure were first visually inspected to identify outlier results and to confirm that variance was approximately constant over the concentration interval (see online Supplemental Fig. 2 ). Fig. 2 shows selected examples of characteristic bias and imprecision findings exhibited by many of the routine measurement procedures. Examples include measurement procedures that exhibited small biases across the concentration range studied ( Fig. 2A) , measurement procedures that had visual evidence of substantial bias (Fig. 2B) , biases that tended to vary with concentration in a nonconstant manner (Fig. 2C) , or procedures that showed increased scatter in addition to bias that varied with concentration (Fig.  2D) .
Error-component analysis was performed to quantify the error sources for each routine measurement procedure vs IDMS (Table 2) . Bias was within Ϯ10% of the IDMS procedure for the BN II and DCA procedures for all concentrations. Biases exceeded Ϯ10% over the interval for all other routine procedures. Agreement generally did not improve when the analysis was restricted to concentrations within the AMR (see online Supplemental Fig. 2 ). Mean bias ranged from Ϫ35% to 34% for concentrations near 15 mg/L, with 13 of 16 procedures exceeding Ϯ10% bias (Table 2) . At the threshold of 30 mg/L, 9 measurement procedures had biases that exceeded Ϯ10% of the IDMS values. The Dimension ExL and RxL had mean biases of approximately Ϫ13% to Ϫ15% for samples with concentrations above the AMRs, and smaller biases of 3% to 6% within the AMR (Fig. 3) , suggesting introduction of error due to an inappropriate dilution matrix. The Immulite 2000 and Dimension Vista data also showed evidence of potential dilution errors for concentrations above the AMR (see online Supplemental Fig. 2) .
Method-comparison results for the semiquantitative Clinitek Advantus measurement procedure are shown in online Supplemental Fig. 3 Imprecision was assessed as part of the errorcomponent analysis. All routine measurement procedures and the IDMS procedure had Ͻ6.6% intraassay imprecision (CV e ) ( Table 2 ). The Dimension RxL had an interassay imprecision (CV b ) of 11.7% (Table 2) ; all other methods were Յ5.4%. Position effects were Յ3.9% and represent variation that is attributed to the position of the sample within a run and may be caused by calibration drift or other nonrandom effects.
Sample-specific effects represent variation in biases that are not explained by the other error components. The sample-specific effects for the routine methods were corrected for the 3.4% sample-specific effects caused by freeze-thaw on the IDMS results. The influence of sample-specific effects (CV d ) was 0% to 15.2% for all routine measurement procedures ( Table 2 ). The Note that routine procedures other than those shown also had similar characteristics (see online Supplemental Fig. 2 ). The solid line represents the line of equivalence. The hashed vertical line represents the upper limit of the analytical measurement range for each routine procedure. Continued on page XX distributions of percent differences for individual samples vs the IDMS procedures are shown in online Supplemental Fig. 4 . Total CVs (CV t ) included combined estimates of intraassay, interassay, position, and sample-specific effects (Table 2 ). CV t for 11 routine procedures ranged from 5.2% to 8.1%. Larger CV t estimates for the Architect series (13.2%-15.7%) were primarily due to large sample specific effects; for the Dimension ExL (12.7%) due to large CV b ; and for the Dimension RxL (10.4%) due to all of the error sources.
Discussion
One goal of the NKDEP Laboratory Working Group and the IFCC Work Group for Standardization of Albumin in Urine is to improve the standardization of results for urine albumin measured by use of different measurement procedures. The data reported here indicate that the current state of agreement among results from 16 quantitative and 1 semiquantitative commercially available routine measurement procedures is inadequate to facilitate use of fixed clinical decision points as currently recommended in national and international guidelines (2) (3) (4) (5) 7 ) . Some routine measurement procedures exhibited relatively small biases compared with the IDMS procedure. However, most procedures exhibited substantial biases that varied with concentration (-35% to 34%). The observation of nonconstant bias indicates that some calibration strategies are inadequate to define the relationship between signal and concentration. Among other factors, calibration procedures may include too few calibrators to sufficiently define the response over the measurement interval, or the diluent used to prepare calibrators at different concentrations may alter the calibrator matrices. The manufacturers of the affected measurement procedures need to address the nonconstant bias over the measuring interval as part of an effort to improve standardization of results.
Several measurement procedures (Immulite 2000 and Dimension series) had evidence of an altered bias when high-concentration samples were diluted into the AMR to obtain the reported concentrations. This observation suggests a matrix influence due to the dilution buffer or a problem with the calibration relationship in the concentration range of the diluted samples. The package inserts for these methods either did not specify the composition of the dilution buffer or did not recommend a dilution factor, or both. To limit Tables 3  and 5 . e Sample-specific effects; based on patient samples. Sample-specific effects for routine methods were corrected for confounding influence of IDMS sample-specific effects due to subjecting the samples to a single freeze-thaw cycle. f Includes CV e , CV b , CV c , and CV d . g Approximate bias was estimated by the moving average of 21 consecutive differences. h Assumed to be zero for the IDMS method. i Sample-specific effects for IDMS were due to freeze-thaw. j Sample-specific effects due to freeze-thaw were not included in CV t for the IDMS method. k Between-run CVs for Architect c4000, c8000, and c16000 were based on manufacturer QC samples rather than on study QC samples because the study QC results were erratic at the beginning and end of different runs, suggesting the samples may have been mishandled or unsuitable for these procedures. Study QC results for the Architect series are shown in online Supplemental Table 7 . l Mean for Vitros 5600 was calculated at 767 mg/L because upper AMR was limited to 1064 mg/L. m Mean for Cobas c 501was calculated at 17 mg/L because lower AMR was limited to 12 mg/L. n Sample-specific variance for Dimension RxL was negative (CV expressed as zero), possibly due to the large between-run imprecision.
the influence of dilution-related matrix effects, manufacturers need to ensure that their recommended dilution buffers do not cause matrix interferences, and they need to validate the maximum dilution values for which their methods are expected to meet performance claims.
The recent Kidney Disease: Improving Global Outcomes guideline (3 ) includes recommendations for use of urine albumin to classify CKD and predict risk of progression. The guidelines recommend use of an albumin-to-creatinine ratio of 30 mg/g (which corresponds to a urine albumin concentration of approximately 30 mg/L) as a lower decision threshold (3 ) . At a concentration of 30 mg/L, 9 routine measurement procedures had mean biases exceeding Ϯ10%, which would contribute to misclassification of CKD risk ( Table 2 ). In addition, 3 of these same procedures had imprecision at 26 mg/L that exceeded a combined CV of 10% (see online Supplemental Table 7 ) and would further contribute to misclassification at the decision threshold. The results for the Clinitek semiquantitative procedure had substantial variation vs the IDMS procedure as demonstrated by the observation that the reported Clinitek value could be either higher or lower than would be predicted on the basis of the measured IDMS concentration, thus causing misclassification of risk. Recent studies have demonstrated that the risk of cardiovascular disease, adverse kidney outcome, and all-cause mortality varies continuously with urine albumin concentration, and significant risk is present at concentrations as low as 10 mg/L (12 ) . Improvements in standardization and performance of urine albumin measurement procedures are needed to enable further research to refine the clinical decision thresholds, particularly at lower albumin concentrations.
Imprecision was generally good with combined CVs of Ͻ10% except for the Architect series and the Dimension ExL and RxL. The error-component attributable to sample-specific effects was a major contributor to combined CV for some procedures, whereas for others the analytical imprecision components were more dominant. Nine samples were removed from the statistical analysis as outliers among 5 measurement procedures (0.2% of total study results). These discrepancies may reflect the presence of a matrix interference or altered form of albumin in those samples. However, the number of outliers was small, and for all methods except the Architect series, the modest sample-specific effects suggest that the urine matrices did not generally introduce clinically significant variation. Using this same sample set, Lieske et al. (10 ) reported that IDMS albumin concentrations were found to exhibit little variation irrespective of whether a fragment near the C or N terminus of the molecule was used for quantification. The molecular forms of albumin in urine that define the measurand are unknown (7, 13 ) . Consequently, the observed errors may be caused by diversity in molecular forms of albumin or other unidentified matrix components.
There are no consensus analytical goals for total error, bias, or imprecision for urine albumin measurements. The intraindividual biologic variation obtained from 25 reports varied from 4% to 103% (expressed as CV) with a central tertile of 28%-47% (7 ). In view of this wide range of estimates, it is not reasonable to speculate on appropriate analytical performance requirements until more reliable estimates of biologic variation are available for persons with moderately increased, but stable, urine albumin excretion. However, the magnitude of bias and imprecision re- ported here indicates that performance improvement is needed.
Strengths of this experimental design include the use of a large number of nonfrozen clinical urine samples handled under conditions similar to those used for clinical laboratory testing. This approach avoided confounding influences of changes in albumin or matrix components from storage conditions. The samples were collected at 3 locations over 10 weeks to ensure a broad sampling of clinical conditions for which urine albumin was measured. The analyses by the routine procedures were performed on 10 separate days to improve averaging of measurement conditions. The comparison procedure to assess bias was a wellcharacterized IDMS method calibrated with highly purified monomeric albumin. The error-component analysis allowed estimation of error contributions due to various sources to minimize confounding among error sources and provide useful information on possible ways to address specific types of errors.
A limitation of the study was that logistical constraints required measurements made by use of the IDMS procedure to be performed by use of samples stored frozen until the end of the collection period. Freezing and thawing caused a mean 3.8% bias in IDMS results. This bias was corrected for comparison to nonfrozen results from the routine procedures. The confounding influence of sample-specific effects due to freeze-thaw on the IDMS results was removed from the estimates of sample-specific effects for routine methods. We did not evaluate frozen storage for up to 90 days at Ϫ70°C for the IDMS procedure. However, there are published reports that support no changes in urine albumin for up to 3 years frozen at Ϫ70°C (8 ) .
Another limitation was the short duration of freezing, 45 min, to assess the influence of a freeze-thaw cycle on results from the routine measurement procedures. It is possible that the samples did not reach temperature equilibration at Ϫ70°C before they were allowed to thaw during shipment. Consequently, these freeze-thaw data can be used to conclude there were minimal influences on albumin immunoreactivity caused by the conditions investigated, but should not be used to make conclusions on longer-term storage at Ϫ70°C. QC samples were to be analyzed at the beginning and end of each batched run over 10 weeks, and we intended to use the QC results to estimate position effects for the routine measurement procedures. However, several manufacturers did not appropriately follow the study design protocol for placement of QC samples. Consequently, data from the freeze-thaw study were used to estimate position effects with the assumption that the nonfrozen and frozen-thawed samples were randomly distributed in a run. Because differences in results between frozen and nonfrozen samples were negligible, it was unlikely that estimates of position effects were confounded by the effects of freeze-thaw.
Other limitations were failure to place QC samples at the beginning and end of runs caused exclusion of several runs in the between-run imprecision estimates for some routine procedures (see online Supplemental Table 4 ). Furthermore, relatively large differences in results for QC samples placed at the beginning and end of some runs for a few routine procedures suggested that evaporation might have occurred. These two limitations could have contributed to overestimation of interassay imprecision for some procedures. Finally, the routine procedure results were obtained by use of single lots of reagents and calibrators; consequently it is possible that other lots may have different performance characteristics.
In conclusion, bias was found to be the dominant source of disagreement among routine measurement procedures. Consequently, standardization of calibration traceability is needed and is expected to improve agreement of results among measurement procedures. However, the bias varied with concentration over the measuring interval for 14 of 16 quantitative procedures and was as large as Ϫ35% to 34% at some concentrations. The variation of bias with concentration needs to be addressed by manufacturers as part of the standardization process. For at least 4 procedures, dilution of samples with high concentrations introduced bias. Consequently, dilution buffers and protocols should be validated to ensure accurate results. Combined imprecision for some procedures exceeded 10%, which should be improved to enable appropriate measurements, especially for low concentrations that may influence CKD risk assessment. Sample-specific influences were dominant sources of imprecision for the Architect series but for most routine procedures did not appear to be an important factor in by use of urine albumin results to make clinical decisions about CKD. 
